Author

P. T. Keiser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A.-L. Barabasi· 1 shared C. J. Donahue· 1 shared C. O'Leary· 1 shared D. Anderson· 1 shared D. M. Gysi· 1 shared F. Wagner· 1 shared G. Menichetti· 1 shared H. Mori· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A.-L. Barabasi

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.

J. Patten, P. T. Keiser, D. M. Gysi, G. Menichetti, H. Mori, C. J. Donahue, X. Gan, I. F. do Valle, K. Geoghegan-Barek, M. Anantpadma, R. Boytz, J. L. Berrigan, S. Hulsey-Stubbs, K. T. Ayazika, C. O'Leary, , R. A. Davey

The paper identifies 389 small molecules and 813 host targets that inhibit SARS-CoV-2 infection through in vitro and in vivo testing, using computational integration of drug activity and cellular networks.

bioRxiv · Apr 20, 2021 · PreprintMicrobiology